Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been increasingly recommended in the treatment of type 2 diabetes (T2DM) due to their favorable effects on improving glycemic control and reducing the risk of cardiovascular events (2, 3). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.